Back to top

BDX Launches New Polymer Syringe

Read MoreHide Full Article

BD Medical, a segment of Medical technology major Becton, Dickinson and Company (BDX - Free Report) , has launched a new prefillable polymer syringe, which is specially engineered to deliver large volume of drugs by intravenous infusion. Due to its high infusion rate, the syringe can be used for anesthesia, pain management, cardiac therapy and nutrition amongst others.

The advanced syringe is made with a highly advanced cyclic olefin polymer that is enable to provide several advantages to drug manufacturers and healthcare professionals including reduced breakage, glass-like transparency, and low levels of extractables. Along with a specific coating technology, this special type of polymer provides smooth gliding, delivering an accurate and consistent infusion rate.

The syringe also facilitate a seamless transition for healthcare workers as its unique design avoids any syringe pump reprogramming activity for hospitals and helps reduce risks of administration errors for healthcare workers. Moreover, the syringe is highly durable, resulting in lower flange breakage and reliable connection with syringe pumps

Becton, Dickinson and Company reported a marginal 1.3% rise in third quarter fiscal 2013 adjusted earnings per share from continuing operations to $1.54, beating the Zacks Consensus Estimate of $1.47. Revenues went up 3.6% (up 5.1% in constant currency or CER) to $2,052.7 million, which were marginally ahead of the Zacks Consensus Estimate of $2,050 million.

At BD Medical, global revenues rose 6.6% (up 7.9% at CER) to $1140.5 million in the quarter, driven by healthy revenues from Medical Surgical Systems, Diabetes Care and Pharmaceutical Systems.

Becton Dickinson reiterated its guidance for fiscal 2013. The company expects sales growth for fiscal 2013 in the range of 3.5% to 4% (growth of 5.0% at CER) compared with 4.5% to 5.0% earlier).

BDX also continues to expect reported earnings per share from continuing operations for fiscal 2013 in a band of $5.72−$5.75. The projection implies a year-over-year rise of 6.5%−7.0% (8.5%−9.0% at CER) for fiscal 2013 or 11.0%−11.5% after accounting for the medical device tax implemented in Jan 2013.

Currently, BDX carries a Zacks Rank #3 (Hold). Other medical stocks that are worth considering include Alphatec Holdings, Inc. (ATEC - Free Report) , The Cooper Companies Inc. (COO - Free Report) and Align Technology Inc. (ALGN - Free Report) . These stocks carry a Zacks Rank #2 (Buy).

More from Zacks Analyst Blog

You May Like